Weber T, Weber R G, Kaulich K, Actor B, Meyer-Puttlitz B, Lampel S, Büschges R, Weigel R, Deckert-Schlüter M, Schmiedek P, Reifenberger G, Lichter P
Abteilung Organisation komplexer Genome, Deutsches Krebsforschungszentrum, Heidelberg, Germany.
Brain Pathol. 2000 Jan;10(1):73-84. doi: 10.1111/j.1750-3639.2000.tb00244.x.
We performed a genome wide screening for genomic alterations on a series of 19 sporadic primary central nervous system lymphomas (PCNSL) of the diffuse large B-cell type by comparative genomic hybridization (CGH). The tumors were additionally analyzed for amplification and rearrangement of the BCL2 gene at 18q21 as well as for mutation of the recently cloned BCL10 gene at 1p22. Eighteen tumors showed genomic imbalances on CGH analysis. On average, 2.1 losses and 4.7 gains were detected per tumor. The chromosome arm most frequently affected by losses of genomic material was 6q (47%) with a commonly deleted region mapping to 6q21-q22. The most frequent gains involved chromosome arms 12q (63%), 18q and 22q (37% each), as well as 1q, 9q, 11q, 12p, 16p and 17q (26% each). High-level amplifications were mapped to 9p23-p24 (1 tumor) and to 18q21-q23 (2 tumors). However, PCR-based analysis, Southern blot analysis and high-resolution matrix-CGH of the BCL2 gene revealed neither evidence for amplification nor for genetic rearrangement. Mutational analysis of BCL10 in 16 PCNSL identified four distinct sequence polymorphisms but no mutation. Taken together, our data do not support a role of BCL2 rearrangement/amplification and BCL10 mutation in PCNSL but indicate a number of novel chromosomal regions that likely carry yet unknown tumor suppressor genes or proto-oncogenes involved in the pathogenesis of these tumors.
我们通过比较基因组杂交(CGH)技术,对19例散发的弥漫大B细胞型原发性中枢神经系统淋巴瘤(PCNSL)进行了全基因组范围的基因组改变筛查。此外,还对这些肿瘤进行了18q21处BCL2基因的扩增和重排分析,以及1p22处最近克隆的BCL10基因的突变分析。18例肿瘤在CGH分析中显示出基因组失衡。平均每个肿瘤检测到2.1个缺失和4.7个增益。基因组物质缺失最常累及的染色体臂是6q(47%),常见的缺失区域定位于6q21-q22。最常见的增益涉及染色体臂12q(63%)、18q和22q(各37%),以及1q、9q、11q、12p、16p和17q(各26%)。高水平扩增定位于9p23-p24(1例肿瘤)和18q21-q23(2例肿瘤)。然而,基于PCR的分析、Southern印迹分析以及BCL2基因的高分辨率矩阵CGH均未发现扩增或基因重排证据。对16例PCNSL的BCL10进行突变分析,鉴定出4种不同的序列多态性,但未发现突变。综上所述,我们的数据不支持BCL2重排/扩增和BCL10突变在PCNSL中的作用,但表明一些新的染色体区域可能携带着尚未知的肿瘤抑制基因或原癌基因,参与了这些肿瘤的发病机制。